sellWeak cluster of 4
Christopher Yea sold $26k of KALV
CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc.. 1,954 shares at an average of $13.42, traded Aug 25, 2025, filed Aug 26, 2025.
Warning score
20Value
$26k
1,954 shares
Holdings after
132,052
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +5Trade size$26k at market
- 0Share of holdings soldSold 1.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-023070, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | MOption exercise Common Stock | +3,125 | - | - | 134,006 | Aug 26, 2025 |
| Aug 25, 2025 | SOpen-market sale Common Stock | -1,954 | $13.42 | $26k | 132,052 | Aug 26, 2025 |
| Aug 22, 2025 | MOption exercise Restricted Stock Unitderivative | -3,125 | $0.00 | $0 | 34,375 | Aug 26, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | KALVsell KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. owner | $3.7M 214,631 shares | -4% | |
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $108k 6,693 shares | -1% | |
| 24Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $83k 5,354 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $156k 10,034 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $68k 4,347 shares | -2% | |
| 32Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $28k 1,767 shares | -11% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $62k 3,975 shares | -8% | |
| 15Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $17k 1,163 shares | -1% | |
| 25Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $16k 1,038 shares | -0% | |
| 15Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $17k 1,109 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.